📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 13:45
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
41 announcements match the current filters (relevance ≥ 5).
10% Revenue Growth in Q1 FY27; Animal Nutrition and Oil Palm Drive Performance
Godrej Agrovet reported a 10% YoY increase in consolidated sales to ₹2,852 Cr for Q1 FY27, despite macro headwinds like a delayed monsoon. Growth was primarily driven by the Animal Nutrition segment (+12.6% revenue) and Oil Palm (+28.9% revenue), while the standalone Crop Care business saw a 16.2% decline. Notably, Astec LifeSciences reached EBITDA breakeven compared to an ₹11 Cr loss in the previous year, and the Dairy segment increased its value-added product salience to 49%. Management highlighted significant improvements in average net working capital and continued focus on portfolio diversification.
Confidence: HIGH
What changedThe company has successfully turned around Astec LifeSciences to EBITDA breakeven and significantly increased the contribution of high-margin value-added products in the Dairy business.
Why it mattersThe results demonstrate the company's ability to maintain growth through diversification, reducing its historical dependence on seasonal crop protection and volatile animal feed segments.
Q1 FY27 Revenue: ₹2,852 CrRevenue Growth (YoY): 10%Cattle Feed Volume Growth: 15%Oil Extraction Ratio: 18.8%VAP Salience in Dairy: 49%Astec EBITDA: Breakeven
📅 Short termThe stock may see positive sentiment as strong performance in core segments like Animal Nutrition and Oil Palm offsets the temporary weakness in Crop Care.
📈 Long termStructural improvements in working capital and a shift toward value-added products and CDMO services are likely to enhance long-term ROCE and margin stability.
⚠ Risk flags
- Monsoon dependence for Crop Care segment
- Elevated milk procurement prices impacting Dairy margins
- Geopolitical disruptions affecting input costs
Key Highlights
Consolidated sales reached ₹2,852 Cr, a 10% YoY growth despite a dry June impacting kharif sowing.
Animal Nutrition segment results grew 29% YoY, supported by a 15% volume growth in cattle feed.
Oil Palm revenue surged 28.9% YoY with the Oil Extraction Ratio (OER) improving to 18.8% from 18.4%.
Dairy segment's value-added product (VAP) share rose to 49% of sales from 42% in the prior year.
Astec LifeSciences achieved EBITDA breakeven, recovering from an ₹11 Cr loss in Q1 FY26.
👀 What to Watch
Investors should monitor the scale-up of new product launches in Crop Care (Ashitaka, Takai) to see if they can offset the volatility in the cotton herbicide segment. Additionally, track the impact of elevated milk procurement prices on Dairy margins in the upcoming quarters.
Q1 FY27: Godrej Agrovet Revenue grows 10% to Rs 2,852 Cr; PAT drops 14% on Crop Care weakness
Godrej Agrovet reported a 10% YoY revenue growth in Q1 FY27, reaching Rs 2,852 Cr, led by strong performance in Animal Nutrition and Oil Palm. However, consolidated PAT declined 14% to Rs 128 Cr as EBITDA margins contracted to 8.9% from 10.8% in the previous year. The decline was primarily driven by the Crop Care segment, where revenue fell 17% due to the driest June in over a decade. The company announced a strategic 'structural reset,' including the exit from Live Bird Trading and a review of the Shrimp Feed business to focus on higher-margin segments.
Confidence: HIGH
What changedThe company has initiated a structural portfolio reset, moving away from a commodity-led mindset to a customer-facing approach, which includes closing the Live Bird Trading business and evaluating the closure of select underperforming plants.
Why it mattersThis strategic shift aims to improve overall ROCE and margins by allocating capital to high-growth areas like CDMO (Astec) and value-added dairy, reducing the impact of volatile commodity cycles.
Q1 FY27 Sales: Rs 2,852 CrPAT (Reported) Growth: -14% YoYCattle Feed Volume Growth: 15%Annual Capex Guidance: Rs 300 - 350 CrCapex vs Net Worth: ~12.1%CPO Realisations: Rs 1,34,783 per MT
📅 Short termThe stock may face near-term pressure due to the 14% PAT decline and margin contraction, though strong volume growth in the feed business provides some fundamental support.
📈 Long termThe structural reset and focus on specialized segments like CDMO and value-added foods could lead to a long-term re-rating if the company successfully improves its ROCE and reduces commodity-linked volatility.
⚠ Risk flags
- Weather dependency (monsoon impact on Crop Care and Palm Oil)
- Commodity price volatility in raw materials for animal feed
- Execution risk in exiting and restructuring business segments
Key Highlights
Consolidated Sales increased 10% YoY to Rs 2,852 Cr, while Reported PAT fell 14% to Rs 128 Cr.
Animal Nutrition segment saw 15% volume growth in Cattle Feed, contributing to a 30% EBIT growth in the India business.
Oil Palm revenue grew 28.9% YoY, supported by an 18.1% increase in CPO realizations and a 43 bps improvement in Oil Extraction Ratio (OER).
Crop Care segment revenue declined 17% and margins dropped 38% due to delayed monsoon impacting cotton herbicide volumes.
Annual capex guidance maintained at Rs 300-350 Cr, representing approximately 12% of the company's current Net Worth.
👀 What to Watch
Watch for the recovery in Crop Care margins in Q2 as monsoon coverage improves and monitor the execution of the planned exit from the low-margin Live Bird Trading business.
Q1 FY27 Results: Revenue up 9.5% to ₹2,852 Cr; PBT declines 8.5% on cost headwinds
Godrej Agrovet reported a 9.5% YoY increase in consolidated sales to ₹2,852 crore for Q1 FY27, driven by strong volume growth in Animal Nutrition and Dairy segments. However, Profit Before Tax (excluding non-recurring items) fell by 8.5% to ₹172 crore due to delayed monsoons impacting Crop Care and milk inflation affecting Dairy margins. Animal Nutrition was a standout performer with a 36% YoY jump in segment results, while Astec LifeSciences continued its recovery toward EBITDA break-even. The Dairy segment saw a significant shift toward value-added products, now comprising 49% of sales compared to 42% last year.
Confidence: HIGH
What changedQ1 FY27 results show revenue growth but margin pressure from input costs and weather-related delays in the agrochemical business compared to the previous year.
Why it mattersThe results demonstrate the company's diversified resilience; strength in Animal Nutrition and Oil Palm is currently offsetting temporary weaknesses in Crop Care and Dairy segments.
Consolidated Sales (Q1 FY27): ₹2,852 crPBT (excl. non-recurring): ₹172 crCattle Feed Volume Growth: 15%Dairy VAP Share: 49%Revenue vs TTM Revenue: 27.87%
📅 Short termThe stock may see a neutral to slightly cautious reaction as the market weighs double-digit volume growth in core segments against the 8.5% decline in PBT.
📈 Long termThe structural shift toward high-margin value-added dairy products and the operational turnaround in Astec LifeSciences are positive indicators for long-term margin expansion.
⚠ Risk flags
- Delayed monsoon impact on Crop Care volumes
- Milk price inflation affecting Dairy profitability
- Geopolitical-led input cost volatility
Key Highlights
Consolidated sales grew to ₹2,852 crore in Q1 FY27 from ₹2,603 crore in Q1 FY26
Animal Nutrition segment results improved by ~36% YoY, supported by 15% growth in cattle feed volumes
Dairy value-added product salience increased to 49% of sales from 42% in the previous year
Bangladesh JV (ACI Godrej) reported a 12% YoY increase in PBT, though PAT was hit by a tax hike to 27.5%
PBT (excluding non-recurring items) stood at ₹172 crore, down from ₹188 crore in the year-ago period
👀 What to Watch
Monitor the recovery in Crop Care volumes as monsoon progresses and track the stabilization of milk procurement prices in the Dairy segment to see if margins recover.
13.8% Profit Dip in Q1; Godrej Agrovet Appoints Ex-HUL Finance Leader as New CFO
Godrej Agrovet reported a mixed Q1 FY27 with consolidated revenue growing 9.2% YoY to ₹2,855.22 Cr, while net profit declined 13.8% to ₹128.31 Cr due to higher operating expenses. The company announced a significant leadership transition, appointing Mr. Ravishankar A. (formerly VP Finance at HUL) as CFO effective October 1, 2026. This follows the early superannuation of current CFO Mr. S. Varadaraj on September 30, 2026. The new CFO brings experience managing a €1.5 billion portfolio, which may impact future capital allocation and strategic M&A.
Confidence: HIGH
What changedGodrej Agrovet is transitioning its financial leadership to an external hire from HUL while reporting a year-on-year decline in quarterly profits despite revenue growth.
Why it mattersThe appointment of a seasoned FMCG finance leader suggests a focus on operational excellence and strategic growth. However, the Q1 profit dip highlights ongoing margin pressures in the agri-business segments.
Q1 Consolidated Revenue: ₹2,855.22 CrQ1 Consolidated Net Profit: ₹128.31 CrQ1 Revenue vs TTM Revenue: ~27.9%YoY Profit Change: -13.8%CFO Effective Date: October 1, 2026
📅 Short termThe stock may face slight pressure due to the YoY profit decline, though the high-quality management appointment could provide some support.
📈 Long termThe new CFO's experience in large-scale FMCG finance and M&A could be structurally positive for Godrej Agrovet's diversification into high-margin CDMO and value-added segments.
⚠ Risk flags
- Margin compression due to rising operating expenses
- Leadership transition risk
Key Highlights
Consolidated revenue for Q1 FY27 increased 9.2% YoY to ₹2,855.22 Cr from ₹2,614.29 Cr.
Consolidated net profit for the quarter fell 13.8% YoY to ₹128.31 Cr from ₹148.83 Cr.
Total expenses rose by 10.8% YoY to ₹2,701.49 Cr, impacting the bottom line.
Mr. Ravishankar A. appointed as CFO-Designate from Sept 21, 2026, and CFO from Oct 1, 2026.
Outgoing CFO Mr. S. Varadaraj to retire effective close of business hours on September 30, 2026.
👀 What to Watch
Monitor the new CFO's strategy regarding margin improvement and capital allocation, especially given the current 8.4% OPM. Watch for the next quarterly results to see if revenue growth can be converted into profit recovery.
Godrej Agrovet Appoints Ex-HUL Executive as CFO; Q1 FY27 PAT at ₹128.3 Cr
Godrej Agrovet has appointed Mr. Ravishankar A, a former Vice President at Hindustan Unilever, as its new Chief Financial Officer effective October 1, 2026. This follows the early superannuation of the current CFO, Mr. S. Varadaraj, who will step down on September 30, 2026. For the quarter ended June 30, 2026, the company reported a 9.2% YoY increase in consolidated revenue to ₹2,855.22 crore, though consolidated PAT declined by 13.8% to ₹128.31 crore. The appointment brings in leadership with experience managing a €1.5 billion portfolio and significant M&A integration expertise.
Confidence: HIGH
What changedThe company is transitioning its financial leadership from a long-term incumbent to an external hire from Hindustan Unilever (HUL).
Why it mattersA CFO change in a ₹10,000+ Cr market cap company is a key governance event; hiring from a top-tier FMCG peer like HUL suggests a focus on improving operational excellence and financial controls.
Q1 FY27 Cons. Revenue: ₹2,855.22 crQ1 FY27 Cons. PAT: ₹128.31 crRevenue Growth (YoY): 9.2%PAT Margin (Q1 FY27): 4.5%New CFO Experience: 20+ years
📅 Short termThe stock may see minor pressure due to the 13.8% YoY decline in quarterly profits, though the high-profile CFO appointment may mitigate negative sentiment.
📈 Long termThe new CFO's expertise in M&A and strategic resource allocation could be pivotal as the company seeks to grow its high-margin CDMO and Vegetable Oil segments.
⚠ Risk flags
- Leadership transition risk
- Margin compression in the latest quarter
- Volatility in raw material prices impacting profitability
Key Highlights
Mr. Ravishankar A appointed as CFO effective October 1, 2026, with a transition period starting September 21, 2026.
Consolidated Revenue for Q1 FY27 grew 9.2% YoY to ₹2,855.22 crore from ₹2,614.29 crore.
Consolidated PAT for Q1 FY27 fell to ₹128.31 crore compared to ₹148.83 crore in the previous year's quarter.
The incoming CFO previously served as VP Finance for HUL's Beauty & Wellbeing business, managing a €1.5 billion portfolio.
Outgoing CFO Mr. S. Varadaraj concludes his tenure on September 30, 2026, citing personal reasons for early superannuation.
👀 What to Watch
Investors should monitor the management transition in late September and watch for any shifts in capital allocation or M&A strategy, given the new CFO's background in portfolio transformation and acquisitions.
Godrej Agrovet Appoints Ravishankar A. as CFO; Q1 FY27 Revenue Grows 9.2% to Rs 2,855 Cr
Godrej Agrovet has announced a significant leadership transition with CFO S. Varadaraj opting for early superannuation effective September 30, 2026. He will be succeeded by Ravishankar A., a seasoned finance leader from Hindustan Unilever, effective October 1, 2026. For Q1 FY27, the company reported consolidated revenue of Rs 2,855.22 crore, up 9.2% YoY, though consolidated PAT declined 13.8% to Rs 128.31 crore compared to Rs 148.83 crore in Q1 FY26. The new CFO brings experience managing a €1.5 billion portfolio at HUL, which may support the company's strategic shift toward high-margin segments.
Confidence: HIGH
What changedThe company is replacing its long-standing CFO with an external hire from Hindustan Unilever and has released its Q1 FY27 financial results.
Why it mattersA change in CFO at a large-cap agri-business is critical for financial discipline and strategic execution, especially as the company targets a 14% growth rate and higher-margin segments like CDMO and Palm Oil.
Q1 FY27 Revenue: Rs 2,855.22 crQ1 FY27 PAT: Rs 128.31 crYoY Revenue Growth: 9.2%Q1 Revenue vs TTM Revenue: 27.9%New CFO Experience: Over 20 years
📅 Short termThe stock may see neutral to slightly cautious sentiment due to the year-on-year decline in profitability despite revenue growth. The management transition is well-planned and unlikely to cause immediate disruption.
📈 Long termThe appointment of a seasoned leader from HUL could strengthen financial governance and strategic M&A execution, supporting the company's long-term diversification goals.
⚠ Risk flags
- Margin compression (PAT down 13.8% YoY)
- Transition risk during leadership change
- Rising operating expenses
Key Highlights
Consolidated Revenue for Q1 FY27 increased to Rs 2,855.22 crore from Rs 2,614.29 crore in Q1 FY26.
Consolidated PAT for the quarter stood at Rs 128.31 crore, down from Rs 148.83 crore in the same period last year.
New CFO Ravishankar A. previously served as VP Finance for HUL's €1.5 billion Beauty & Wellbeing business.
Outgoing CFO S. Varadaraj will step down on September 30, 2026, after a transition period starting September 21, 2026.
Total expenses for the quarter rose 10.8% YoY to Rs 2,701.49 crore, primarily driven by material costs.
👀 What to Watch
Monitor the transition to the new CFO and his impact on capital allocation and margin improvement strategies. Investors should also track if the revenue growth translates into better operating margins in subsequent quarters, given the current YoY PAT decline.
Godrej Agrovet Q1 PAT Falls 13.8% to ₹128 Cr; Appoints HUL Veteran as New CFO
Godrej Agrovet reported a mixed Q1 FY27 with consolidated revenue growing 9.2% YoY to ₹2,855.22 Cr, while net profit declined 13.8% to ₹128.31 Cr. The standalone business faced significant headwinds, with revenue dropping 16.9% YoY to ₹1,667.71 Cr. A major leadership transition was announced: long-time CFO S. Varadaraj will retire on September 30, 2026, to be succeeded by Ravishankar A., a former Vice President at Hindustan Unilever with over 20 years of experience.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and initiated a top-level management transition for the CFO position.
Why it mattersWhile consolidated top-line growth remains positive, the profit decline and standalone revenue contraction indicate operational pressures. The appointment of an HUL veteran as CFO signals a potential focus on FMCG-style operational excellence and governance.
Consolidated Revenue (Q1 FY27): ₹2,855.22 CrConsolidated PAT (Q1 FY27): ₹128.31 CrYoY PAT Growth: -13.8%Standalone Revenue Growth: -16.9%CFO Transition Date: October 1, 2026
📅 Short termThe stock may face pressure due to the double-digit decline in consolidated net profit and weak standalone performance.
📈 Long termThe high-quality CFO appointment from HUL is a positive structural move that could improve long-term financial strategy and investor relations.
⚠ Risk flags
- Margin contraction in consolidated operations
- Significant revenue decline in standalone business
- Key management personnel transition risk
Key Highlights
Consolidated Revenue increased 9.2% YoY to ₹2,855.22 Cr for the quarter ended June 30, 2026
Consolidated Net Profit (PAT) declined 13.8% YoY to ₹128.31 Cr from ₹148.83 Cr
Standalone Revenue saw a sharp decline of 16.9% YoY, falling to ₹1,667.71 Cr
New CFO Ravishankar A. joins from HUL where he managed a €1.5 billion Beauty & Wellbeing portfolio
Consolidated EPS for the quarter decreased to ₹6.99 from ₹8.35 in the year-ago period
👀 What to Watch
Investors should monitor the margin recovery in the standalone business and the strategic direction under the new CFO, particularly regarding capital allocation in high-margin segments like CDMO and Vegetable Oil.
Godrej Agrovet Q1 PAT Declines 13.8% to ₹128 Cr; Appoints Ex-HUL Executive as New CFO
Godrej Agrovet reported a 9.2% YoY increase in consolidated revenue to ₹2,855.22 Cr for Q1 FY27. However, consolidated PAT declined by 13.8% to ₹128.31 Cr compared to ₹148.83 Cr in the same quarter last year, primarily due to a 10.8% rise in total expenses. The company also announced that CFO S. Varadaraj will take early superannuation on September 30, 2026, to be succeeded by Ravishankar A., a seasoned finance leader from Hindustan Unilever, effective October 1, 2026.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial performance and initiated a top-level management transition in the finance department.
Why it mattersThe decline in PAT despite revenue growth highlights margin pressure in the agri-processing business. The appointment of a high-profile executive from HUL as CFO suggests a focus on strengthening financial governance and strategic growth.
Consolidated Revenue (Q1 FY27): ₹2,855.22 CrConsolidated PAT (Q1 FY27): ₹128.31 CrYoY Revenue Growth: 9.2%YoY PAT Growth: -13.8%Cost of Materials Consumed: ₹2,055.51 Cr
📅 Short termThe stock may face mild pressure due to the bottom-line miss, though the appointment of a reputable new CFO could mitigate negative sentiment.
📈 Long termThe leadership change brings expertise in M&A and portfolio transformation from a major FMCG player, which could structurally improve Godrej Agrovet's high-margin segment focus over the next 2-3 years.
⚠ Risk flags
- Rising raw material costs impacting operating margins
- Management transition risk during a period of earnings volatility
Key Highlights
Consolidated Revenue from operations grew 9.2% YoY to ₹2,855.22 Cr in Q1 FY27.
Consolidated Net Profit fell 13.8% YoY to ₹128.31 Cr from ₹148.83 Cr.
Total Expenses increased to ₹2,701.49 Cr, driven by a 17.7% rise in cost of materials consumed to ₹2,055.51 Cr.
New CFO Ravishankar A. joins from HUL where he managed a €1.5 billion Beauty & Wellbeing portfolio.
Standalone results were bolstered by a ₹49.7 Cr dividend received from a joint venture.
👀 What to Watch
Investors should monitor the impact of rising raw material costs on margins in upcoming quarters and watch for any strategic shifts in capital allocation following the new CFO's takeover in October.
Godrej Agrovet Q1 Revenue up 9.2% to ₹2,855 Cr; Net Profit Declines 13.8% YoY
Godrej Agrovet reported a 9.2% YoY increase in consolidated revenue to ₹2,855.22 Cr for Q1 FY27. However, consolidated net profit fell by 13.8% to ₹128.31 Cr compared to ₹148.83 Cr in the same quarter last year, primarily due to a 17.7% surge in raw material costs. The company also announced a major leadership change, appointing Mr. Ravishankar A. (formerly VP Finance at Hindustan Unilever) as the new CFO effective October 1, 2026, following the early superannuation of the current CFO.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results showing top-line growth but bottom-line pressure, alongside a transition in the Chief Financial Officer role.
Why it mattersThe profit decline highlights the impact of commodity price volatility on the agri-business. The appointment of a seasoned finance leader from HUL suggests a potential shift toward tighter financial controls and strategic portfolio management.
Consolidated Revenue (Q1 FY27): ₹2,855.22 CrConsolidated Net Profit (Q1 FY27): ₹128.31 CrYoY Revenue Growth: 9.2%YoY Profit Growth: -13.8%Cost of Materials vs Revenue: 72.0%
📅 Short termThe stock may face pressure due to the double-digit profit decline, though the high-profile CFO appointment from HUL may be viewed positively by institutional investors.
📈 Long termThe structural focus on high-margin segments like CDMO and Vegetable Oil remains key; the new CFO's experience in M&A and transformation could accelerate this shift.
⚠ Risk flags
- Raw material price volatility
- Margin compression (Cost of materials up 17.7% vs 9.2% revenue growth)
- Management transition risk
Key Highlights
Consolidated revenue from operations grew 9.2% YoY to ₹2,855.22 Cr from ₹2,614.29 Cr.
Consolidated net profit attributable to owners fell 16.2% YoY to ₹134.50 Cr from ₹160.52 Cr.
Cost of materials consumed increased significantly to ₹2,055.51 Cr, up from ₹1,746.43 Cr in the previous year's quarter.
Standalone other income included a dividend of ₹49.7 Cr from a joint venture.
New CFO appointment: Mr. Ravishankar A. brings over 20 years of experience from HUL to lead finance from Oct 1, 2026.
👀 What to Watch
Investors should monitor the new CFO's impact on operational efficiencies and margin recovery, as raw material costs currently outpace revenue growth. Watch for the next quarterly update to see if the company can pass on these higher input costs to maintain margins.
Rs 11 Final Dividend: Godrej Agrovet Issues TDS Guidelines and Record Date Details
Godrej Agrovet has issued a formal communication regarding the tax deduction at source (TDS) for its recommended final dividend of Rs 11 per share (110% of face value) for FY 2025-26. The dividend is subject to shareholder approval at the 35th AGM scheduled for August 5, 2026. The record date for determining eligibility is July 29, 2026, with the book closure period starting July 30, 2026. Resident shareholders will be subject to a 10% TDS if their total dividend exceeds Rs 10,000, while non-residents face a 20% withholding tax unless treaty benefits are applied.
Confidence: HIGH
What changedThe company has formalized the administrative and tax procedures for the FY26 final dividend payout, including the setting of the record date and AGM schedule.
Why it mattersThis is a routine but necessary procedural update for shareholders to receive their net dividend payout. It also highlights compliance with the newly enacted Income Tax Act, 2025, and SEBI's electronic-only payment mandate.
Final Dividend: Rs 11 per shareDividend Rate: 110%Record Date: July 29, 2026TDS Threshold (Resident): Rs 10,000Dividend Yield: 1.91%
📅 Short termThe stock is likely to trade ex-dividend around July 29, 2026, which typically results in a minor price adjustment corresponding to the dividend amount.
📈 Long termLimited; this is a routine distribution of profits and does not alter the company's structural growth trajectory.
Key Highlights
Final Dividend recommended at Rs 11 per equity share of face value Rs 10 (110% payout)
Record date for determining dividend entitlement is Wednesday, July 29, 2026
TDS of 10% applicable for resident shareholders with valid PAN if dividend exceeds Rs 10,000
35th Annual General Meeting (AGM) scheduled for August 5, 2026, at 4:00 PM IST
Dividend yield is approximately 1.91% based on the current market price of Rs 576
👀 What to Watch
Shareholders should ensure their PAN is linked with Aadhaar and bank account details are updated with their Depository Participant or RTA by the record date to ensure seamless electronic credit and avoid higher tax deductions.
₹300 Cr Investment: Godrej Agrovet Inaugurates Integrated Oil Palm Complex in Telangana
Godrej Agrovet has inaugurated India's first integrated oil palm complex in Khammam, Telangana, involving a cumulative investment of ₹300 Crore. The facility integrates the entire value chain including a seed garden, nursery, R&D center, and a mill which has commenced operations at 30 tonnes per hour. This investment represents approximately 10.4% of the company's net worth (₹2,895 Cr). The complex is designed to support the company's target of tripling its plantation area in Telangana from 10,000 to 30,000 hectares by 2030.
Confidence: HIGH
What changedGodrej Agrovet has moved from a fragmented supply chain to a fully integrated 'seed-to-refinery' model in Telangana with the inauguration of this new complex.
Why it mattersThe integration improves operational efficiency and oil extraction ratios while securing the supply chain. As the vegetable oil segment is a high-growth area (41% growth previously), this capacity expansion is central to the company's diversification strategy away from animal feed.
Cumulative Investment: ₹300 CroreInvestment vs Net Worth: ~10.4%Initial Mill Capacity: 30 tonnes per hourTarget Plantation Area: 30,000 hectaresCurrent Plantation Area: 10,000 hectares
📅 Short termThe commencement of mill operations is likely to be viewed positively by the market as it signals immediate capacity addition in a key growth segment.
📈 Long termThis is a structural expansion that supports the company's goal of becoming a dominant player in India's edible oil security mission, potentially improving long-term margins through vertical integration.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Climatic risks (extreme heat) impacting oil extraction yields
- Execution risk in tripling plantation area by 2030
- Volatility in global edible oil prices
Key Highlights
Cumulative investment of ₹300 Crore once the entire integrated complex is fully operational
Mill capacity of 30 tonnes per hour commenced, with design provision to scale up to 60 tonnes per hour
Targeting expansion of plantation area from current 10,000 hectares to 30,000 hectares by 2030
Integrated model includes India's first seed-to-refinery setup under one roof to improve quality control
Partnership with global companies for a seed garden to develop climate-resilient hybrid planting material
👀 What to Watch
Investors should monitor the execution timeline for the upcoming refinery within the complex and the annual progress in plantation area expansion, which are critical for scaling the high-margin vegetable oil segment.
Rs 11 Dividend: Godrej Agrovet Announces 35th AGM and Dividend Payment Schedule
Godrej Agrovet has scheduled its 35th Annual General Meeting (AGM) for August 5, 2026, via video conferencing. The company has confirmed a final dividend of Rs 11 per equity share (110% of face value) for the financial year ended March 31, 2026. Shareholders must ensure their KYC and bank details are updated by the cut-off date of July 29, 2026, to receive the payout. The dividend is slated for payment on or before August 10, 2026, following a year where the company reported a TTM PAT of Rs 445 Cr.
Confidence: HIGH
What changedThe company has formalized the timeline for its 35th AGM and the distribution of the Rs 11 per share final dividend for FY 2025-26.
Why it mattersThis is a routine but significant cash return to shareholders, representing a dividend yield of approximately 1.95% based on the current price of Rs 562.6. It confirms the company's commitment to distributing profits from its Rs 445 Cr TTM PAT.
Final Dividend: Rs 11 per shareDividend Yield: ~1.95%Cut-off Date: July 29, 2026Payment Date: August 10, 2026Face Value: Rs 10
📅 Short termThe stock may experience mild support or buying interest leading up to the July 29 cut-off date as investors seek to qualify for the Rs 11 dividend.
📈 Long termLimited structural impact as this is a routine annual corporate action; however, consistent dividend payouts reflect stable cash flow management.
Key Highlights
Proposed final dividend of Rs 11 per equity share, representing 110% of the Rs 10 face value.
Cut-off date for dividend eligibility and e-voting set for Wednesday, July 29, 2026.
Dividend payment to be completed on or before Monday, August 10, 2026.
35th Annual General Meeting scheduled for Wednesday, August 5, 2026, at 4:00 PM IST.
Last date for submission of tax exemption forms (TDS) is Monday, August 3, 2026.
👀 What to Watch
Investors should verify that their PAN and bank account details are linked to their demat accounts before July 29, 2026, to ensure seamless dividend credit. Monitor the upcoming Annual Report for management's outlook on the high-margin CDMO and palm oil segments.
Godrej Agrovet Q4 FY26 Revenue Up 9% to ₹2,333 Cr; Annual Revenue Crosses ₹10,000 Cr
Godrej Agrovet reported a strong Q4 FY26 with consolidated revenue of ₹2,333 crores, a 9% YoY increase, and PBT growth of 16.8% to ₹87 crores. For the full year FY26, the company surpassed the ₹10,000 crore revenue milestone, finishing at ₹10,233 crores with a 17.2% PBT growth. Key drivers included a 15% volume growth in Animal Nutrition and EBITDA break-even for Astec LifeSciences. Management has provided a positive outlook for FY27, targeting double-digit revenue growth and mid-teen PBT growth.
Key Highlights
Full-year FY26 revenue crossed the ₹10,000 crore milestone, reaching ₹10,233 crores (up 9% YoY).
Animal Nutrition Q4 volumes grew 15% YoY, led by a 24% surge in cattle feed volumes.
Astec LifeSciences achieved EBITDA break-even in FY26 with a strong turnaround in CDMO business.
Oil Palm segment achieved record area expansion and all-time high oil extraction ratios.
Management guides for double-digit revenue growth and mid-teens PBT growth in FY27.
👀 What to Watch
The stock remains a strong play on the Indian agri-economy given its diversified portfolio and improving margins. Investors should monitor the recovery in the Crop Care segment and the impact of global palm oil prices in FY27.
Godrej Agrovet FY26 Revenue Surpasses ₹10,000 Cr with All-Time High Profitability
Godrej Agrovet reported a robust FY26 with consolidated revenue growing 9.1% to ₹10,233 crore and PAT increasing 13.9% to ₹440 crore. The Oil Palm business was a standout performer with a 68% growth in segment results, while Animal Nutrition saw strong volume growth of 12%. Despite challenges in the Dairy and Crop Care segments due to high procurement costs and adverse weather, the company significantly optimized its working capital cycle from 45 to 25 days. Return on Capital Employed (ROCE) improved notably to 20% from 13% in the previous year.
Key Highlights
Consolidated revenue crossed the ₹10,000 crore milestone, reaching ₹10,233 crore in FY26.
Oil Palm business EBIT surged 67.9% YoY, driven by improved oil extraction ratios and supportive pricing.
Animal Nutrition segment recorded 18% volume growth in cattle feed, contributing to a 19.3% rise in segment EBIT.
Net Working Capital days significantly optimized from 45 days to 25 days, leading to an improved ROCE of 20%.
Astec LifeSciences achieved an EBITDA break-even turnaround with a sharp reduction in losses compared to FY25.
👀 What to Watch
Investors should take note of the significant improvement in capital efficiency and the turnaround in the Astec LifeSciences subsidiary. The strong performance in core segments like Oil Palm and Animal Nutrition provides a cushion against cyclical pressures in the Dairy and Crop Care divisions.
Godrej Agrovet FY26 Revenue Surpasses ₹10,000 Cr with 17% PBT Growth
Godrej Agrovet reported a robust FY26 performance with consolidated revenue crossing the ₹10,000 crore milestone, marking a 9.1% year-on-year growth. Profit Before Tax (excluding exceptional items) rose by 17.2% to ₹569 crore, driven by a stellar 68% EBIT growth in the Oil Palm business and strong volumes in Animal Nutrition. While the Dairy and Crop Care segments faced headwinds from high procurement costs and adverse weather, the company significantly improved capital efficiency. Net Working Capital days were reduced from 39 to 25, leading to an improved Return on Capital Employed (ROCE) of 20%.
Key Highlights
Consolidated revenue grew 9.1% YoY to ₹10,233 crore, surpassing the ₹10,000 crore mark for the first time.
Oil Palm segment results surged 67.9% YoY to ₹384 crore, supported by peak oil extraction ratios and better pricing.
Animal Nutrition volumes increased by 11.6% YoY, with cattle feed volumes specifically growing by 18%.
Net Working Capital (NWC) optimized significantly from 39 days to 25 days, boosting ROCE from 16% to 20%.
Astec LifeSciences achieved EBITDA break-even in FY26, showing a sharp turnaround from a loss in the previous year.
👀 What to Watch
Investors should view the record revenue and significant improvement in capital efficiency as strong indicators of management's execution capability. The turnaround in Astec LifeSciences and growth in Oil Palm provide a solid margin cushion against volatility in the Dairy and Crop Care segments.
Godrej Agrovet FY26 Revenue Surpasses ₹10,000 Cr; PAT Up 14% to ₹440 Cr
Godrej Agrovet reported a robust FY26 performance with consolidated revenue growing 9.1% to ₹10,233 crore and PAT increasing 13.9% to ₹440 crore. The Oil Palm business was a standout performer with 68% EBIT growth, while the Animal Nutrition segment saw strong 11.6% volume growth. Despite challenges in the Dairy and Crop Care segments due to weather and high procurement costs, the company achieved a significant turnaround in Astec LifeSciences. Notably, the company optimized its net working capital to 25 days, leading to an improved ROCE of 20%.
Key Highlights
Consolidated revenue crossed the ₹10,000 crore milestone, reaching ₹10,233 crore in FY26 (+9.1% YoY).
Oil Palm segment EBIT grew by 68% YoY, driven by improved oil extraction ratios and supportive pricing.
Animal Nutrition volumes grew by 11.6%, with cattle feed specifically rising by 18% during the year.
Net Working Capital days significantly reduced from 45 days in FY24 to 25 days in FY26.
Return on Capital Employed (ROCE) improved to 20% in FY26, up from 13% in FY24.
👀 What to Watch
Investors should monitor the sustained recovery in Astec LifeSciences and the margin trajectory in the Dairy business. The significant improvement in ROCE and working capital efficiency makes the stock a strong watch in the agri-business sector.
Godrej Agrovet FY26 Revenue Surpasses ₹10,000 Cr; PAT Up 14% to ₹445 Cr
Godrej Agrovet reported a robust FY26 with consolidated revenue growing 9.1% to ₹10,233 crore and PAT increasing 13.9% to ₹440 crore (excluding non-recurring items). The performance was driven by strong volume growth in Animal Nutrition (12%) and a landmark year for the Oil Palm business, which saw a 68% jump in segment results. While Crop Care and Dairy faced headwinds from weather and high procurement costs, Astec LifeSciences achieved an EBITDA turnaround. Notably, the company significantly optimized its working capital cycle to 25 days, leading to an improved ROCE of 20%.
Key Highlights
Consolidated revenue crossed the ₹10,000 crore milestone, reaching ₹10,233 crore in FY26.
Oil Palm segment result grew by 67.9% YoY, driven by record oil extraction ratios and supportive pricing.
Animal Nutrition volumes grew 12% YoY, with cattle feed specifically rising by 18%.
Net Working Capital cycle significantly improved from 39 days to 25 days, boosting ROCE to 20%.
Astec LifeSciences achieved EBITDA break-even in FY26 with a sharp reduction in losses.
👀 What to Watch
Investors should monitor the sustained recovery in Astec LifeSciences and the margin stability in the Dairy segment. The company's focus on capital efficiency and branded products in the poultry business makes it a strong long-term play in the agri-conglomerate space.
Godrej Agrovet FY26 Revenue Crosses ₹10,000 Cr; PBT Grows 17% YoY to ₹569 Cr
Godrej Agrovet delivered a strong FY26 performance with consolidated revenue growing 9% YoY to ₹10,233 crore, crossing the ₹10,000 crore milestone. Profit before tax (excluding exceptional items) rose 17% to ₹569 crore, supported by a 68% growth in the Oil Palm segment and a turnaround in Astec LifeSciences which reached EBITDA break-even. While the Animal Nutrition business saw 12% volume growth, the Dairy and Crop Care segments faced headwinds from unseasonal rains and high procurement costs. The company also reported improved working capital management and a tangible increase in ROCE.
Key Highlights
Consolidated FY26 revenue reached ₹10,233 crore, a 9% increase over FY25.
FY26 PBT (excluding non-recurring items) grew 17% YoY to ₹569 crore.
Oil Palm segment results surged by ~68% YoY driven by peak oil recovery and volume growth.
Animal Nutrition volumes grew 12% in FY26, with cattle feed volumes specifically rising 18%.
Astec LifeSciences achieved EBITDA break-even in FY26, marking a significant turnaround from previous losses.
👀 What to Watch
Investors should note the strong recovery in Astec LifeSciences and the robust growth in the Oil Palm and Animal Nutrition segments as key value drivers. While Dairy and Crop Care remain under pressure, the shift toward branded products and improved capital efficiency supports a positive long-term outlook.
Godrej Agrovet FY26 PAT Up 10.4% to ₹445 Cr; ₹11 Dividend Declared
Godrej Agrovet reported a steady financial performance for FY26, with consolidated revenue from operations growing 9% to ₹10,232.68 crore. Full-year consolidated net profit increased by 10.4% to ₹445.18 crore, supported by a strong Q4 performance where profit jumped to ₹102.28 crore from ₹66.10 crore YoY. The Board has recommended a final dividend of ₹11 per share (110% of face value). The company also announced the allotment of 30,973 shares under its ESOP scheme.
Key Highlights
Consolidated Revenue for FY26 rose to ₹10,232.68 crore, up from ₹9,382.77 crore in FY25.
Full-year Consolidated Profit After Tax (PAT) grew 10.4% YoY to ₹445.18 crore.
Recommended a final dividend of ₹11.00 per equity share (110%) for FY 2025-26.
Q4 FY26 consolidated PAT stood at ₹102.28 crore, a significant jump from ₹66.10 crore in the same quarter last year.
Paid-up equity share capital increased to ₹192.36 crore following the allotment of 30,973 ESOP shares.
👀 What to Watch
Investors may find the steady earnings growth and healthy dividend yield attractive; focus should remain on the company's ability to maintain margins amidst fluctuating agri-commodity prices.
Godrej Agrovet FY26 PAT Rises 10% to ₹445 Cr; Recommends ₹11 Dividend
Godrej Agrovet reported a steady financial performance for FY 2025-26, with consolidated revenue growing 9.1% YoY to ₹10,232.68 crore. Net profit for the year increased by 10.4% to ₹445.18 crore, supported by improved operational efficiencies. The Board has recommended a substantial final dividend of ₹11 per share (110% of face value). Additionally, the company managed its employee stock options by allotting 30,973 shares and granting 50,507 new options to eligible employees.
Key Highlights
Consolidated Revenue from Operations grew 9.1% YoY to ₹10,232.68 crore in FY26.
Consolidated Net Profit (PAT) increased to ₹445.18 crore from ₹403.37 crore in the previous fiscal.
Recommended a final dividend of ₹11.00 per equity share for the financial year 2025-26.
Basic Earnings Per Share (EPS) rose to ₹24.58 compared to ₹22.35 in FY25.
Allotted 30,973 equity shares and granted 50,507 new stock options under the ESGS 2018 scheme.
👀 What to Watch
The steady earnings growth and healthy dividend payout make this a positive result for long-term investors. Shareholders should monitor the upcoming AGM on August 5, 2026, for further management commentary on growth outlook.
